Credit: Pfizer. Eucrisa (crisaborole) ointment, 2%, is now approved for the treatment of mild to moderate atopic dermatitis in pediatric patients as young as 3 months old. Eucrisa (crisaborole) ...

EUCRISA is the first and only 100% steroid-free, topical prescription medication approved for patients as young as 3 months of age in the United States AD is a chronic skin disease characterized by ...

The Food and Drug Administration (FDA) has approved Eucrisa (crisaborole ointment; Pfizer) for the treatment of mild to moderate atopic dermatitis in patients aged ≥2 years. The Food and Drug ...

Pfizer has gained FDA approval for Eucrisa, a new eczema treatment which could achieve peak annual sales of $2 billion a year. The drug is significant because it is the first non-steroidal therapy for ...

Pfizer Inc. PFE announced top-line results from a late-stage study, which evaluated its PDE4 inhibitor, Eucrisa (crisaborole ointment, 2%), for the treatment of mild to moderate atopic dermatitis (AD) ...

EUCRISA™ is a new, steroid-free, topical ointment for mild to moderate atopic dermatitis (eczema) 1 First prescription treatment indicated for mild to moderate AD to be approved in more than 10 years ...

EUCRISA® (crisaborole) ointment, 2%, IMPORTANT SAFETY INFORMATION FROM THE U.S. PRESCRIBING INFORMATION Do not use EUCRISA if you are allergic to crisaborole or any of the ingredients in EUCRISA.

Nearly 18 million children and adults across the United States live with atopic dermatitis (AD), also known as eczema. 1 About 90 percent of those with eczema have the mild-to-moderate form of the ...

Atopic dermatitis, also known as eczema, is a skin condition that may affect people of all races and ethnicities, but may occur more frequently in African-American children. [1] According to US ...

Jessica Simpson has revealed for the first time ever that she's battle eczema since she was a child. In a sponsored post on her Instagram account for Eucrisa ointment, the 40-year-old told her 5.5 ...

ALLEGAN, Mich., Sept. 28, 2021 /PRNewswire/ -- Padagis announced today that Anacor Pharmaceuticals, Inc initiated patent litigation on September 24, 2021 in the U.S. District Court for the district of ...